59
Views
1
CrossRef citations to date
0
Altmetric
other

Phenprobamate use disorder: a case report

ORCID Icon & ORCID Icon
Pages 115-117 | Received 13 Mar 2020, Accepted 04 Jun 2020, Published online: 18 Jun 2020
 

ABSTRACT

Background: Tolerance and dependence of centrally acting muscle relaxants have been reported in the medical literature for nearly 50 years. Meprobamate, which is one of the best-known examples, had been a controlled substance after studies indicating its addictive effects, shortly after its introduction in the 1950 s. Phenprobamate, which has been reported to be similar to meprobamate in terms of effects, side effects, and toxicity, is not a controlled substance and is frequently prescribed as a centrally acting 10 muscle relaxant. To our knowledge, there is only one case report regarding phenprobamate dependence, which is known for its similar mechanism of action to meprobamate.

Methods and Results: Here a case study, who is taking 12 grams a day (30 tablets/day), is presented about phenprobamate, which could have an addictive effect similar to some centrally acting muscle relaxants that were reported in the literature.

Conclusions: Physicians should investigate non-phenprobamate muscle relaxant options in those with a history of 15 alcohol and substance use disorders, and health policy should prevent over-the-counter drug sales and prevent possible addictions.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.